EUVIMEDEUVIMED entdecken
Crossref

Absolute Risk of Progression to Cognitive Impairment Based on Plasma Phosphorylated Tau 217, Age, Sex, and APOE ε4

Alicia Algeciras-Schimnich, Mingzhao Hu, Stephen D. Weigand, Terry M. Therneau, Heather J. Wiste, Michael E. Griswold, Daniel J. Figdore, Joshua A. Bornhorst, Prashanthi Vemuri, David S. Knopman, Jonathan Graff-Radford, Ronald C. Petersen und 28 weitere

JAMA Neurology · 16.11.2026

DOI: 10.1001/jamaneurol.2026.4292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Neurology, online erschienen am 16.11.2026. Verfasst von Alicia Algeciras-Schimnich und 39 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Alzheimer disease (AD) pathology can be detected years before symptom onset, but some individuals who are biomarker positive and cognitively unimpaired (CU) remain asymptomatic.

Objective

To estimate 5- and 10-year absolute risks of mild cognitive impairment (MCI) and dementia using continuous plasma phosphorylated tau 217 (p-tau217) and p-tau217/amyloid β 42 (Aβ42). Design, Setting, and Participants This cohort study included participants from the Mayo Clinic Study of Aging (MCSA) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Participants were CU individuals aged 60 to 90 years with baseline Fujirebio Lumipulse plasma p-tau217 measurements, APOE genotyping, and longitudinal clinical follow-up. The MCSA is a population-based longitudinal cohort of residents in Olmsted County, Minnesota; ADNI is a multicenter observational cohort. MCSA data were ascertained from October 2008 to September 2025; ADNI data from September 2005 to January 2026. Exposures Age, sex, APOE ε4, p-tau217, and p-tau217/Aβ42. Main Outcomes and Measures Transition from CU to MCI and dementia estimated using continuous-time multistate models.

Results

In the MCSA cohort (n = 1644), the median (IQR) age was 72 (66-79) years; 804 participants (49%) were female and 840 (51%) were male. In the ADNI cohort (n = 534), the median (IQR) age was 72 (68-77) years; 297 participants (56%) were female and 237 (44%) were male. A p-tau217 of 0.324 pg/mL vs 0.072 pg/mL (90th vs 10th percentile) was associated with 2.66 (95% CI, 2.02-3.51), 3.02 (95% CI, 2.21-4.12), 2.62 (95% CI, 1.99-3.46), and 2.79 (95% CI, 2.04-3.81) greater hazard of clinical progression in MCSA female participants who did not carry the APOE ε4 variant (ε4−), females who did carry the APOE ε4 variant (ε4+), males who were ε4−, and males who were ε4+, respectively. In ADNI, hazards were 2.67 (95% CI, 1.86-3.85), 2.83 (95% CI, 1.89-4.22), 2.08 (95% CI, 1.48-2.92), and 3.99 (95% CI, 2.59-6.13), respectively. In MCSA, higher baseline p-tau217 and older age were associated with greater absolute risk of progression. At age 75 years and assuming sex and APOE are at the MCSA means of 0.511 and 0.268, 5-year absolute risk of MCI increased from 7% (95% CI, 5%-8%) to 17% (95% CI, 13%-20%) for a p-tau217 concentration of 0.072 vs 0.324 pg/mL; 10-year absolute risk of MCI increased from 15% (95% CI, 12%-18%) to 35% (95% CI, 29%-41%; P < .001 for both). At 0.324 pg/mL, 5-year MCI risk increased from 6% (95% CI, 4%-8%) to 37% (95% CI, 32%-43%) for ages 65 to 85 years; 10-year risks were 17% (95% CI, 12%-21%) and 66% (95% CI, 57%-74%; P < .001 for both). Results were similar for p-tau217/Aβ42. Conclusions and Relevance This study found that higher plasma p-tau217 and older age were associated with higher 5- and 10-year risk of cognitive impairment. Plasma p-tau217 concentrations, combined with age, sex, and APOE ε4 status, can enable individualized estimation of short-term absolute risk of cognitive impairment in CU individuals, with applications in prognosis and trial enrichment in preclinical AD.

Zitieren

APA

Algeciras-Schimnich, A., Hu, M., Weigand, S. D., Therneau, T. M., Wiste, H. J., Griswold, M. E., Figdore, D. J., Bornhorst, J. A., Vemuri, P., Knopman, D. S., Graff-Radford, J., Petersen, R. C., Jack, C. R., Raya, M. A., Abusalim, A., Acevedo, M., Acothley, S., Acree, A., Adegoke, O., …, & Arcuri, D. (2026). Absolute Risk of Progression to Cognitive Impairment Based on Plasma Phosphorylated Tau 217, Age, Sex, and APOE ε4. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2026.4292

Vancouver

Algeciras-Schimnich A, Hu M, Weigand SD, Therneau TM, Wiste HJ, Griswold ME, et al. Absolute Risk of Progression to Cognitive Impairment Based on Plasma Phosphorylated Tau 217, Age, Sex, and APOE ε4. JAMA Neurology. 2026. doi:10.1001/jamaneurol.2026.4292

BibTeX
@article{AlgecirasSchimnich2026,
  author = {Algeciras-Schimnich, Alicia and Hu, Mingzhao and Weigand, Stephen D. and Therneau, Terry M. and Wiste, Heather J. and Griswold, Michael E. and Figdore, Daniel J. and Bornhorst, Joshua A. and Vemuri, Prashanthi and Knopman, David S. and Graff-Radford, Jonathan and Petersen, Ronald C. and Jack, Clifford R. and Raya, Maison Abu and Abusalim, Ala and Acevedo, Mara and Acothley, Skieff and Acree, Allison and Adegoke, Olusegun and Hussen, Kedir Adem and Adhikari, Alisa and Aggarwal, Ruchi and Ahmed, Tuba and Aisen, Paul and Ajayi, Adeyinka and Ajtai, Bela and Aladeen, Traci and Al-Amin, Jahmila and Albers, Colleen and Albert, Marilyn and Alo, Tolulope and Alosco, Michael and Aloszka, Deborah and Amaza, Hannatu and Amoyaw, Marie and Amtashar, Fatima S. and Anderson, Brandon and Anderson, Karen and Apostolova, Liana G. and Arcuri, Daniel},
  title = {Absolute Risk of Progression to Cognitive Impairment Based on Plasma Phosphorylated Tau 217, Age, Sex, and APOE ε4},
  journal = {JAMA Neurology},
  year = {2026},
  doi = {10.1001/jamaneurol.2026.4292}
}
Kostenlos starten →